56. ベーチェット病 Behcet disease Clinical trials / Disease details
臨床試験数 : 76 / 薬物数 : 110 - (DrugBank : 32) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000012469 | 2013/12/02 | 02/12/2013 | Comparison of Adalimumab and Steroid in Intestinal Behcet's disease | Comparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study | Intestinal Behcet's disease | Subcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously. Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately | Castle Study Group | NULL | Recruiting | 15years-old | Not applicable | Male and Female | 50 | Not selected | Japan |
2 | NCT00931957 (ClinicalTrials.gov) | October 2010 | 30/6/2009 | Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease | Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease | Behcet Syndrome;Uveal Disease | Drug: Etanercept, Methotrexate, Prednisolone | Tehran University of Medical Sciences | Wyeth is now a wholly owned subsidiary of Pfizer | Recruiting | 16 Years | 60 Years | Both | 80 | N/A | Iran, Islamic Republic of |